Citigroup Issues Positive Forecast for West Pharmaceutical Services (NYSE:WST) Stock Price

West Pharmaceutical Services (NYSE:WST) had its price target hoisted by Citigroup from $412.00 to $494.00 in a research note published on Friday,Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

Several other analysts have also commented on the company. Weiss Ratings raised West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. Morgan Stanley raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $365.00 to $400.00 in a research note on Tuesday, September 22nd. Barclays upped their target price on West Pharmaceutical Services from $440.00 to $500.00 and gave the stock an “overweight” rating in a research note on Friday. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Saturday, October 24th. Twelve investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $409.67.

West Pharmaceutical Services Trading Down 0.9%

WST stock opened at $412.73 on Friday. The company’s 50-day simple moving average is $367.76 and its 200-day simple moving average is $313.21. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 52-week low of $223.83 and a 52-week high of $438.27. The firm has a market cap of $29.05 billion, a P/E ratio of 46.32, a PEG ratio of 2.75 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.20 by $0.46. The firm had revenue of $874.50 million for the quarter, compared to analysts’ expectations of $827.12 million. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the firm earned $1.96 EPS. As a group, equities analysts forecast that West Pharmaceutical Services will post 9.45 EPS for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 18th. Investors of record on Wednesday, November 11th will be paid a $0.26 dividend. The ex-dividend date of this dividend is Tuesday, November 10th. This represents a $1.04 dividend on an annualized basis and a yield of 0.3%. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. West Pharmaceutical Services’s dividend payout ratio is 11.67%.

Insider Transactions at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Annette Favorite sold 2,524 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $365.00, for a total transaction of $921,260.00. Following the completion of the sale, the vice president directly owned 21,818 shares in the company, valued at approximately $7,963,570. The trade was a 10.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 15,659 shares of company stock valued at $5,443,749. Insiders own 0.60% of the company’s stock.

Hedge Funds Weigh In On West Pharmaceutical Services

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $2,387,990,000. State Street Corp increased its holdings in shares of West Pharmaceutical Services by 1.7% in the second quarter. State Street Corp now owns 3,348,698 shares of the medical instruments supplier’s stock valued at $1,202,183,000 after purchasing an additional 54,920 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $733,733,000. Generation Investment Management LLP purchased a new position in West Pharmaceutical Services during the second quarter worth approximately $728,168,000. Finally, Findlay Park Partners LLP purchased a new position in West Pharmaceutical Services during the second quarter worth approximately $214,196,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

More West Pharmaceutical Services News

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.